Categories: News

Hardy Diagnostics Presents: Detection of Carbapenemase Producing Organisms; Advancements and Barriers to the Clinical Laboratory

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

Free educational webinar hosted by Hardy Diagnostics offered with continuing education credits

Join!

Join!Join!
Join!

SANTA MARIA, Calif., Sept. 21, 2021 (GLOBE NEWSWIRE) — Carbapenemase-resistant Enterobacterales (CRE) are a major concern for patients in health care facilities. Some bacteria in this family are resistant to nearly all antibiotics, leaving only more toxic or less effective treatment options.

To learn more about the utility of screening for Carbapenem-resistant Enterobacterales and the technologies that are available to do so, Hardy Diagnostics is pleased to offer a free webinar titled, “Detection of carbapenemase-producing organisms; advancements and barriers to the clinical lab,” on Oct. 7, 2021, at 11 a.m. PST/1 p.m. CST.

Led by Nathan Ledeboer, PhD, D(ABMM), F(AAM) this discussion will:

  • Discuss the utility of screening for CRE from clinical specimens.
  • Contrast the difference between carbapenemase-producing organisms with carbapenem-resistant organisms.
  • Evaluate technologies available to screen for carbapenemases from stool, rectal swabs and from bacterial colonies.
  • Discuss the pros and cons of implementing a CRE screening program.  

Dr. Nathan Ledeboer is a Professor and Vice Chair of Pathology at the Medical College of Wisconsin, and Medical Director of Microbiology, Molecular Diagnostics, reference services, and laboratory client services at Froedtert Hospital and Wisconsin Diagnostic Laboratories. He is also the editor of the Journal of Clinical Microbiology

This free webinar is presented by Hardy Diagnostics.

C.E. credits are offered in partnership through the Northern California Branch of the American Society of Microbiology (NCASM) LFS #400.

Click here to register for this educational webinar. For more information, contact Megan Roesner at roesnerm@hardydiagnostics.com.

To learn more about the products offered at Hardy Diagnostics to detect and diagnose disease, please visit www.hardydiagnostics.com.

Related Images

Image 1: Join!

This content was issued through the press release distribution service at Newswire.com.

Attachment

Staff

Recent Posts

Relief Therapeutics Advances Publication of 2025 Half-Year Report

GENEVA, SWITZERLAND / ACCESS Newswire / August 11, 2025 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY…

2 hours ago

HistoIndex Marks Another Step Forward with FibroSIGHT™ Plus: Introducing AI-based Quantitative Analysis in Fibrosis Assessment

SINGAPORE, Aug. 10, 2025 /PRNewswire/ -- HistoIndex, a pioneering leader in digital pathology solutions for…

5 hours ago

TERRY COLE FIX IT! DEA Blocks FDA Cannabis Trials While Contaminated Marijuana Floods State Markets

Terrance Cole's Choice: Reformer or Cover-Up Artist? New DEA Administrator Terrance Cole stands at a…

23 hours ago

Unlock the Power of MK-677: Your Guide to Buying MK-677 Ibutamoren Online

Buy MK-677 Ibutamoren capsules online to boost growth hormone and IGF-1 levels. Discover the benefits…

1 day ago

Top 6 Best Joint Supplements for Dogs to Support Canine Joint Health and Pain Relief

Discover the best joint supplement for dogs designed to promote joint health, reduce arthritis symptoms,…

1 day ago